Clinical Trial: A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients >= 12yo With Dystrophic Epidermolysis Bullosa

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07926867) titled 'A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients >= 12yo With Dystrophic Epidermolysis Bullosa' on Nov. 03.

Brief Summary: Dystrophic epidermolysis bullosa (DEB) is an inherited mucocutaneous fragility disorder caused by pathogenic variants in COL7A1, leading to blistering, scarring, and significant morbidity. Pruritus is a major complication that substantially impairs patients' quality of life, yet effective treatment options remain limited. Nemolizumab, an interleukin-31 receptor alpha antagonist, inhibits IL-31 signaling, a pathway potentially involved in DEB-associated pruritus. Elevat...